Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries
| Autor: | Yvetta Vantuchová, Petr Arenberger, Karel Ettler, Martina Kojanová, Alena Machovcova, Petra Cetkovská, Jiří Štork, Martin Tichý, Jorga Fialová |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Coronary Disease Hyperlipidemias Comorbidity Dermatology Overweight Severity of Illness Index Body Mass Index Acitretin 030207 dermatology & venereal diseases 03 medical and health sciences Psoriatic arthritis Keratolytic Agents 0302 clinical medicine Risk Factors Psoriasis Area and Severity Index Diabetes mellitus Psoriasis Internal medicine Diabetes Mellitus Prevalence medicine Humans Obesity Registries Czech Republic Retrospective Studies Biological Products business.industry Dermatology Life Quality Index Middle Aged Phototherapy medicine.disease Methotrexate 030220 oncology & carcinogenesis Hypertension Retreatment Cohort Cyclosporine Quality of Life Female Dermatologic Agents medicine.symptom business medicine.drug |
| Zdroj: | International Journal of Dermatology. 56:428-434 |
| ISSN: | 0011-9059 |
| Popis: | Background BIOREP is a Czech registry of psoriatic patients on biological treatment in a clinical setting. We describe the characteristics of patients with psoriasis at the time of enrollment and present comparisons with published data from other national registries. Methods We analyzed the cohort of patients treated with biologics between May 2005 and May 2015. Demographic data, previous therapies, comorbidities, and severity of psoriasis were compared with data from other registries – DERMBIO, BIOBADADERM, BADBIR, and PSOBEST. Results A total of 1412 psoriatic patients initiating biological treatment were included with a predominance of males (63.4%). The mean patient age was 50.2 years, and approximately 70.5% of patients were either overweight or obese. The mean baseline Psoriasis Area and Severity Index was 19.8, and the Dermatology Life Quality Index was 16.6. More than one-third of patients (41.0%) reported a history of psoriatic arthritis, and a high proportion of patients (49.5%) with cardiovascular risk factors (hypertension [35.2%], hyperlipidemia [27.7%], diabetes mellitus [11.4%], coronary heart disease [4.9%], and obesity [15.2%]) were observed. Most of the patients had been previously treated with phototherapy (85.4%), acitretin (74.0%), methotrexate (65.7%), or cyclosporine (53.1%). Conclusion BIOREP is one of the first registries of patients with psoriasis treated with biologics in Central and Eastern Europe. Our results found a similar or higher prevalence of comorbidities, long disease duration, and high impact on the quality of life among patients included in Western European registries. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text